Jackson Square Capital’s Pfizer PFE Stock Holding History

Jackson Square Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-95	Closed	-$3K	–	287
2020 Q3	$3K	Sell	95 -585	-86%	-$20.5K	﹤0.01%	317
2020 Q2	$21K	Sell	680 -768	-53%	-$26.1K	0.01%	198
2020 Q1	$45K	Sell	1,448 -2,305	-61%	-$78.5K	0.04%	127
2019 Q4	$140K	Buy	+3,753	New	+$134K	0.08%	110

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Jackson Square Capital's PFE Position: Q4 2020 in Review

Jackson Square Capital sold out of Pfizer (PFE) in Q4 2020, closing a stake of 95 shares — an estimated $3K sold.

Jackson Square Capital first reported a position in PFE in Q4 2019 and held it in 4 quarters. The position peaked at $140K in Q4 2019. 2,674 funds tracked by Wall St. Rank hold PFE as of Q4 2020.

Jackson Square Capital reported no remaining Pfizer position as of Q4 2020 after selling out during the quarter.
Jackson Square Capital sold 95 Pfizer shares in Q4 2020, an estimated $3K.
Jackson Square Capital first reported a position in Pfizer in Q4 2019 and held it in 4 quarters.
Jackson Square Capital's Pfizer position peaked at $140K in Q4 2019.
2,674 funds tracked by Wall St. Rank held Pfizer as of Q4 2020.

Based on Jackson Square Capital's 13F filing for Q4 2020, filed 5 Mar 2021.